Cargando…
The Current Landscape of Antibody-based Therapies in Solid Malignancies
Over the past three decades, monoclonal antibodies (mAbs) have revolutionized the landscape of cancer therapy. Still, this benefit remains restricted to a small proportion of patients due to moderate response rates and resistance emergence. The field has started to embrace better mAb-based formats w...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738893/ https://www.ncbi.nlm.nih.gov/pubmed/33391547 http://dx.doi.org/10.7150/thno.52614 |
_version_ | 1783623220134412288 |
---|---|
author | Shah, Ashu Rauth, Sanchita Aithal, Abhijit Kaur, Sukhwinder Ganguly, Koelina Orzechowski, Catherine Varshney, Grish C Jain, Maneesh Batra, Surinder K |
author_facet | Shah, Ashu Rauth, Sanchita Aithal, Abhijit Kaur, Sukhwinder Ganguly, Koelina Orzechowski, Catherine Varshney, Grish C Jain, Maneesh Batra, Surinder K |
author_sort | Shah, Ashu |
collection | PubMed |
description | Over the past three decades, monoclonal antibodies (mAbs) have revolutionized the landscape of cancer therapy. Still, this benefit remains restricted to a small proportion of patients due to moderate response rates and resistance emergence. The field has started to embrace better mAb-based formats with advancements in molecular and protein engineering technologies. The development of a therapeutic mAb with long-lasting clinical impact demands a prodigious understanding of target antigen, effective mechanism of action, gene engineering technologies, complex interplay between tumor and host immune system, and biomarkers for prediction of clinical response. This review discusses the various approaches used by mAbs for tumor targeting and mechanisms of therapeutic resistance that is not only caused by the heterogeneity of tumor antigen, but also the resistance imposed by tumor microenvironment (TME), including inefficient delivery to the tumor, alteration of effector functions in the TME, and Fc-gamma receptor expression diversity and polymorphism. Further, this article provides a perspective on potential strategies to overcome these barriers and how diagnostic and prognostic biomarkers are being used in predicting response to mAb-based therapies. Overall, understanding these interdependent parameters can improve the current mAb-based formulations and develop novel mAb-based therapeutics for achieving durable clinical outcomes in a large subset of patients. |
format | Online Article Text |
id | pubmed-7738893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-77388932021-01-01 The Current Landscape of Antibody-based Therapies in Solid Malignancies Shah, Ashu Rauth, Sanchita Aithal, Abhijit Kaur, Sukhwinder Ganguly, Koelina Orzechowski, Catherine Varshney, Grish C Jain, Maneesh Batra, Surinder K Theranostics Review Over the past three decades, monoclonal antibodies (mAbs) have revolutionized the landscape of cancer therapy. Still, this benefit remains restricted to a small proportion of patients due to moderate response rates and resistance emergence. The field has started to embrace better mAb-based formats with advancements in molecular and protein engineering technologies. The development of a therapeutic mAb with long-lasting clinical impact demands a prodigious understanding of target antigen, effective mechanism of action, gene engineering technologies, complex interplay between tumor and host immune system, and biomarkers for prediction of clinical response. This review discusses the various approaches used by mAbs for tumor targeting and mechanisms of therapeutic resistance that is not only caused by the heterogeneity of tumor antigen, but also the resistance imposed by tumor microenvironment (TME), including inefficient delivery to the tumor, alteration of effector functions in the TME, and Fc-gamma receptor expression diversity and polymorphism. Further, this article provides a perspective on potential strategies to overcome these barriers and how diagnostic and prognostic biomarkers are being used in predicting response to mAb-based therapies. Overall, understanding these interdependent parameters can improve the current mAb-based formulations and develop novel mAb-based therapeutics for achieving durable clinical outcomes in a large subset of patients. Ivyspring International Publisher 2021-01-01 /pmc/articles/PMC7738893/ /pubmed/33391547 http://dx.doi.org/10.7150/thno.52614 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Shah, Ashu Rauth, Sanchita Aithal, Abhijit Kaur, Sukhwinder Ganguly, Koelina Orzechowski, Catherine Varshney, Grish C Jain, Maneesh Batra, Surinder K The Current Landscape of Antibody-based Therapies in Solid Malignancies |
title | The Current Landscape of Antibody-based Therapies in Solid Malignancies |
title_full | The Current Landscape of Antibody-based Therapies in Solid Malignancies |
title_fullStr | The Current Landscape of Antibody-based Therapies in Solid Malignancies |
title_full_unstemmed | The Current Landscape of Antibody-based Therapies in Solid Malignancies |
title_short | The Current Landscape of Antibody-based Therapies in Solid Malignancies |
title_sort | current landscape of antibody-based therapies in solid malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738893/ https://www.ncbi.nlm.nih.gov/pubmed/33391547 http://dx.doi.org/10.7150/thno.52614 |
work_keys_str_mv | AT shahashu thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT rauthsanchita thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT aithalabhijit thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT kaursukhwinder thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT gangulykoelina thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT orzechowskicatherine thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT varshneygrishc thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT jainmaneesh thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT batrasurinderk thecurrentlandscapeofantibodybasedtherapiesinsolidmalignancies AT shahashu currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT rauthsanchita currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT aithalabhijit currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT kaursukhwinder currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT gangulykoelina currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT orzechowskicatherine currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT varshneygrishc currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT jainmaneesh currentlandscapeofantibodybasedtherapiesinsolidmalignancies AT batrasurinderk currentlandscapeofantibodybasedtherapiesinsolidmalignancies |